**FORM PTO-1083** 



I hereby certify that this correspondence is

being deposited with the United States Postal

Service with sufficient postage as first class

mail in an envelope addressed to: Commissioner for Patents

Washington D.C. 20231, on

(Not Assigned)

(Not Assigned)

April 4, 2002

Name

Signature

Date of Deposit

Heather B. Del Bosco

13054.02300

04/04/02

Date

## ANTER NITED STATES PATENT AND TRADEMARK OFFICE

Art Unit:

Examiner:

In re application of: Arthur D. LANDER, et al. Serial No: 09/807,575

Filed: July 12, 2001

For: GLYPICANS FOR THE DETECTION AND TREATMENT

OF HUMAN CARCINOMA

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an amendment in the above-identified application.

Small entity status has been claimed. See 37 CFR § 1.27.

A PC-MS Windows formatted CD-ROM is enclosed with sequence listing: (1) file glypicans.txt (2KB), created on April 4, 2002.

A paper version of the "Sequence Listing" is enclosed.

No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NUME PREVIOUSLY PAI		(Col. 3) PRESENT EXTRA*	LG/S \$ ENTITY		 DD'L E DUE
TOTAL CLAIMS FEE	16	-	16	**		LG=\$18 SM=\$9	\$9	\$ 0
INDEPENDENT CLAIMS FEE	4	-	4	***		LG=\$84 SM=\$42	\$42	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS  LARGE ENTITY FEE = \$280 SMALL ENTITY FEE = \$140								\$ 140
							TOTAL	\$ 0

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

A check in the amount of \$	to cover the additional	claims fee is enclosed.	A copy of this sheet is
enclosed.			

A check in the amount of \$\_\_\_ to cover the extension fee is enclosed. A copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1796, referencing docket number 13054.02300. A copy of this sheet is enclosed.

Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims

Any patent application processing fees under 37 C.F.R. § 1.17

Respectfully submitted, CROSBY, HEAFEY, ROACH & May


Date: April 4, 2002

1901 Avenue of the Stars, Suite 700

Los Angeles, CA 90067 Phone: (310) 734-5200 Fax: (310) 734-5299 CROSBY, HEAFEY, ROACH &

Stefan J. Kirothanski Registration No. 36,568 Attorney for Applicant(s)

10/16/1998



Commissioner for Patients, flor 9f 4 United States Patent and Trackensatic Office Washington, 11 C., 2020

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

09/807,575

Arthur Lander
13054.02309

INTERNATIONAL APPLICATION NO.

PCT/US99/24176

I.A. FILING DATE PRIORITY DATE

28983 CROSBY HEAFEY ROACH & MAY 1901 AVENUE OF THE STARS, SUITE 700 LOS ANGELES, CA 90067

CONFIRMATION NO. 9101
371 FORMALITIES LETTER
\*OC0000000007707959\*

10/15/1999

Date Mailed: 03/28/2002

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- . U.S. Basic National Fee
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Diskette
- Copy of the International Application
- Copy of the International Search Report
- · Oath or Declaration
- Request for Immediate Examination
- Small Entity Statement

DOCKETED CHRM - KH

APR 0: 2002

DUE: 4/28/2002

FINAL: 4/28/2002 RECEIVED

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).



- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

## ANITA D JOHNSON

Telephone: (703) 305-3661

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
09/807,575	PCT/US99/24176	82351.0003

FORM PCT/DO/EO/916 (371 Formalities Notice)